Article

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Author(s):

Ben Leach

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Linda Gillam, MD, MPH | Credit: Atlantic Health System
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Allysa Saggese, NP | Credit: Weill Cornell Medicine
Zobair Younossi, MD, MPH | Credit: American College of Gastroenterology
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Related Content
AHA Scientific Statement Promotes Expanded Use of Lipoprotein Apheresis | Image Credit: USNews
October 11th 2024

AHA Scientific Statement Promotes Expanded Use of Lipoprotein Apheresis

Connor Iapoce
Taher Modarressi, MD | Credit: X.com
October 3rd 2024

Don't Miss a Beat: Putting Evidence-Based Cardiometabolic Therapies into Practice, with Taher Modarressi, MD

Muthiah Vaduganathan, MD, MPH Stephen Greene, MD
Topiramate, Pregabalin Reduce Headache Frequency, Intensity in Pediatric Migraine
October 11th 2024

Topiramate, Pregabalin Reduce Headache Frequency, Intensity in Pediatric Migraine

Chelsie Derman
MEDCast Podcast logo
October 1st 2024

Exploring Oral Systemic Therapies for Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Lauren Miller, MPAS, PA-C Jayme M Heim, MSN, FNP-BC Kirk Gautier, PA-C
FDA logo
October 11th 2024

FDA Approves Marstacimab-hncq (Hympavzi) for Hemophilia A or B Without Inhibitors

Victoria Johnson
Graded Oral Challenge Safe, Effective for Pediatric Macrolide Allergy
October 11th 2024

Graded Oral Challenge Safe, Effective for Pediatric Macrolide Allergy

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.